Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Trial Updates and Multiple Myeloma

View overview page
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
3:12
Updated results of the LINKER-MM1 trial: linvoseltamab in R/R multiple myeloma
Sundar Jagannath • 7 Apr 2024
0:58
Dara-RVd in the treatment of HR-SMM: an ongoing Phase II trial
Irene Ghobrial • 11 Dec 2023
2:44
Dual-targeting bispecific antibody alnuctamab in R/R multiple myeloma
Maria-Victoria Mateos • 9 Dec 2023
2:26
Preliminary results of GEM2017FIT: comparing induction therapies in fit elderly patients with MM
Maria-Victoria Mateos • 9 Dec 2023
3:51
Should HR-SMM be treated before progression to NDMM?
Ola Landgren • 20 Dec 2023
3:31
ADVANCE: Dara-KRd versus KRd in patients with NDMM
Ola Landgren • 20 Dec 2023
2:16
What does the future of MGUS look like?
Sæmundur Rögnvaldsson • 10 Dec 2023
3:26
The risk of thrombotic events in patients with MGUS: an analysis from the iStopMM trial
Sæmundur Rögnvaldsson • 10 Dec 2023
2:02
Alnuctamab, a BCMA x CD3 TCE, in the treatment of multiple myeloma
Luciano Costa • 11 Dec 2023
2:40
Dual-targeting of Slamf-7 and CD38 with elotuzumab and isatuximab in multiple myeloma
Luciano Costa • 11 Dec 2023
1:29
Replacing dexamethasone in transplant-ineligible multiple myeloma: the REST study
Fredrik Schjesvold • 11 Dec 2023
1:21
The REMNANT study: will treating patients at MRD relapse improve survival outcomes?
Fredrik Schjesvold • 11 Dec 2023
1:53
An update on the progress made in CAR T-cell therapy in India
Gaurav Narula • 15 Feb 2024
2:04
Isatuximab, carfilzomib, lenalidomide, and dexamethasone in multiple myeloma: the SKylaRk trial
Elizabeth O'Donnell • 11 Dec 2023
1:41
Dara-RVD, with an MRD-adaptive duration of therapy, in high-risk smoldering myeloma
Omar Nadeem • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals